Bone density diseases such as osteoporosis affect a significant number of people worldwide. 
Introduction
Bone density disorders such as osteoporosis are well-established diseases that affect 1 in 5 men, as well as 200 million women worldwide, with 1 in 3 women over 50 experiencing osteoporotic fractures.
1,2 Bone is a porous structure that is constantly being remodelled, with the process of bone formation by osteoblasts and bone resorption by osteoclasts being tightly regulated under normal conditions. Any imbalance within the remodelling process leads to bone resorption diseases such as osteoporosis, characterised by decreased bone mass and poor bone quality. This leads to increased risk of fracture, in the order of 40% in developed countries, and can lead to serious complications in the elderly. The morbidity and mortality associated with osteoporosis gives rise to high personal and nancial costs.
To date, the most useful method for the prevention and treatment of osteoporosis is through pharmaceutical intervention with bisphosphonates. Bisphosphonates are the synthetic mimic of the pyrophosphate moiety found in bone mineral and act by inhibiting the resorption of bone by inactivating osteoclasts. Whilst being effective forms of treatment for osteoporosis, there are a number of signicant disadvantages of bisphosphonates such as unwanted side-effects. Oral bisphosphonates such as alendronate can lead to upper gastrointestinal problems; patients must take the medication on an empty stomach, at the same time each morning and must stay fully upright for 30 minutes aer therapeutic ingestion. Such stringent dosing regimens oen lead to poor patient compliance, reducing intestinal absorption and the efficacy of the medicine. As bisphosphonates accumulate in the bone, their safety in long-term use has recently been questioned by several researchers, including the Food and Drug Administration (FDA).
3,4
Hydroxyapatite (HAP) is the main mineral component of bone. Both biological and synthetic HAP crystallise in the hexagonal form having the P6 3 /m space group and including two formula units per cell, each with 44 atoms and a Ca/P ratio of 1.67. 5, 6 An important property of HAP is its ability to undergo substitution of both cations and anions. [7] [8] [9] [10] [11] It is interesting to note that within the HAP unit cell there are two crystallographically distinct calcium sites, Ca(1) and Ca(2), with some cations displaying preferential substitution for one site over the other.
12-14
Lanthanides, including the 14 4f-block elements as well as lanthanum, are considered bone-seekers as they are known to have a high affinity for bone due to their strong interaction with the inorganic phosphate in hydroxyapatite. 15, 16 Many lanthanides exhibit physicochemical similarities with calcium. For instance, trivalent lanthanum and divalent calcium share similar ionic radii and donor atom preferences but the higher charge on La 3+ can lead to a high affinity for Ca 2+ sites in biological molecules. [17] [18] [19] Bone is constantly being remodelled through formation of new bone by osteoblasts and resorption by osteoclasts. This can lead to substitution of Ca 2+ ions with La 3+ within bone and, through this continuous remodelling cycle of bone, lanthanides can affect cellular activity and potentially exert a positive inuence on bone mineral.
20,21
Lanthanum, in the form of lanthanum carbonate (La 2 (CO 3 ) 3 , Fosrenol™) is currently used to treat hyperphosphatemia, a condition caused by elevated phosphate levels in the blood. There is a demonstrated dose-dependent accumulation of lanthanum in bone with long retention times. [22] [23] [24] Lanthanum inuences the bone histology and bone-resorption activity of osteoclasts in vitro. [25] [26] [27] Therefore lanthanum has been proposed as a potential preventative measure for osteoporosis; however, its low bioavailability requires that high doses be administered, leading to adverse gastrointestinal tract side effects. 28 Altering the chemical environment around the La(III) ions through use of chelating ligands has the potential to mitigate these adverse effects and improve both the oral bioavailability of La(III) and the bone-targeting ability. Bisphosphonates, the current preferred treatment of bone resorption diseases, show a high affinity for HAP. Ln(III) does as well, and its incorporation into an appropriate chelating ligand could serve to more selectively target the Ln(III) to the bone. 29 We have therefore engaged in an ongoing project that explores the use of lanthanide complexes for the treatment of osteoporosis and other bone density disorders. [30] [31] [32] Our goal has been to identify suitable chelators of lanthanum having the potential to increase the bioavailability of the metal ion while reducing unwanted side effects by lowering the concentrations required and controlling the delivery of the metal. Based on solubility parameters, lipophilicity, hydroxyapatite binding studies, cellular uptake, and cytotoxicity, we have identied two compounds possessing the desired properties: 3-hydroxy-1,2-dimethylpyridin-4(1H)-one (Hdpp) and a phosphinate-EDTA derivative, bis[[bis(carboxy-methyl)amino]methyl]phosphinate (H 5 XT) (Fig. 1) . When compared to the clinically used lanthanum carbonate, the complexation of La by Hdpp improves cellular uptake, shows low cellular toxicity (EC 50 > 100 mM in MG-63 cells) and may improve the oral bioavailability of the metal ion in vivo. Chelators containing phosphonate groups are already used to target radionuclides to bone for diagnostic or therapeutic purposes [33] [34] [35] [36] and the presence of the phosphinic acid group on H 5 XT can be expected to have a similar bonetargeting ability. We have previously investigated the ionexchange of a series of lanthanides with hydroxyapatite and quantied the thermodynamics of this ion-exchange process by isothermal titration calorimetry (ITC).
37
In this paper we expand upon the biological studies of Barta 30 and Mawani 31 and report in vitro time-dependent studies of La 3+ binding to hydroxyapatite, along with equilibrium binding constants (K a s) determined by ITC. We also report for the rst time in vivo data for the two lead compounds, La(dpp) 3 and La(XT), including the pharmacokinetics and tissue distribution of La(dpp) 3 following a single dose to rats, as well as tissue and bone distribution of La 3+ following multiple doses of La(dpp) 3 and La(XT).
Results and discussion
Plasma and tissue clearance and pharmacokinetics of La(dpp) 3 A plot of La 3+ plasma concentration versus time from Sprague Dawley (SD) rats (n ¼ 6) administered La(dpp) 3 intravenously at a dose of 1 mg kg À1 at time 0 h is shown in Fig. 2 . The corresponding La 3+ concentration in organs analysed by ICP-MS following this are shown in Fig. 3 . The pharmacokinetic parameters derived by non-compartmental analysis are shown in Table 1 . When administered as the complex, La(dpp) 3 , plasma levels of lanthanum show a peak (C 0 ) of 4973 AE 557 ng mL À1 which rapidly decreased to approximately 10% of C 0 within 6 hours and back to pre-dose concentrations ($15 ng mL À1 ) within 24 hours. Clearance of La 3+ from plasma Fig. 1 Structures of the metal-ligand complexes formed between La 3+ and Hdpp (La(dpp) 3 , left) and H 5 XT (La(XT), right), the two lead compounds in this study. ), signicantly less than for the liver and spleen. This is consistent with previous studies indicating the liver is the main organ of excretion for lanthanum and the kidneys play a negligible role in its elimination following intravenous doses of La 2 (CO 3 ) 3 .
38-40
Tissue distribution of La(dpp) 3 and La(XT) following multiple doses
The distribution of lanthanum in organs and bone in SD rats (n ¼ 6) following the administration of multiple intravenous doses of either La(dpp) 3 or La(XT) are shown in Fig. 4 (tissue) and Fig. 5 (bone). The rst point to note is that the organ distribution of La 3+ is similar for both La(dpp) 3 and La(XT 3 , 1320 AE 157 ng g À1 for La(XT)). Plasma levels aer 5 days of treatment were similar for both La(dpp) 3 and La(XT) (5517 AE 1188 ng g À1 and 5999 AE 302 ng g À1 ), respectively. No signicant difference in metal-ion distribution was recorded between the two complexes except for differences in animal-to-animal variation in tissue and plasma concentrations. From Fig. 4 and Table S1 , † larger inter-animal variability is noted for La(dpp) 3 . A possible cause of the variability may lie with the differences in thermodynamic stability of the complex and/or its kinetic inertness in vivo. The difference in denticity of the two chelating ligands investigated will inuence the stability and speciation of the metal ion as discussed later.
From Fig. 5 the bone distribution of lanthanum appears slightly greater in animals treated with La(XT) compared to La(dpp) 3 . Statistical analysis of the datasets for uptake of lanthanum derived from either La(dpp) 3 or La(XT) in the hip, mid and knee sections of bone by one-way ANOVA gave p-values of 0.006, 0.017 and 0.004, respectively. The difference in lanthanum uptake may be due to a number of factors: the thermodynamic stability of the La(XT) complex (log
is greater than that for
La(dpp) 3 (log b ML3 ¼ 17.44, pM of 5.8) and/or the presence of the phosphinate group in XT may improve the targeting of lanthanum to bone.
31,32
It is also worth noting that consistently higher levels of La
3+
were detected in the knee section of the femur versus the hip and middle sections, suggesting regions of higher bone turnover actively incorporate La 3+ ions into the bone structure more rapidly. The lanthanum detected in bone was consistently and signicantly greater than background levels in untreated SD rats (41.9 AE 12.4 ng g À1 ). The low background levels were less than 5% of detected La 3+ in treated animals. Fig . 4 Tissue distribution of the lanthanum from the complexes, La(dpp) 3 and La(XT), after multiple intravenous dose administrations at 1 mg kg À1 per day for 5 days in SD rats (n ¼ 6; mean AE SD).
Overall, lanthanum is rapidly cleared from the blood with redistribution to bone, as well as certain tissues, predominantly the liver and spleen. This is consistent with previous ndings that show the initial uptake of lanthanide elements is in the liver followed by redistribution to the bone. (Fig. S1A and B †) again provide an explanation; they show that at the higher pH, very little free Bone (femur) distribution of lanthanum from the complexes La(dpp) 3 and La(XT) after multiple doses of 1 mg kg À1 per day for 5 days in SD rats (n ¼ 6; mean AE SD). In contrast to the Hdpp ligand, at pH 5 the phosphinate-EDTA derivative, H 5 XT, was found by ITC to bind HAP in the absence of La 3+ (Fig. 6C ). In the presence of H 5 XT, binding of La 3+ to HAP is also observed at pH 5 by ITC (Fig. 6D ), but is weaker in nature. Regrettably, in this case, the complex contributions from background binding of the ligand to HAP, as well as the high heat of dilution of the ion-loaded ligand, confounded efforts to regress a K d value for La 3+ absorption.
Similar results were obtained at pH 7.4, with the added complication that binding was considerably slower (resulting in signicant titration peak broadening) and, for the case of binding of the H 5 XT ligand alone, each titration exhibited an initial endothermic process followed by a slow exothermic event (Fig. S2 †) . Complex binding of multidentate anionic ligands has been observed before, as evidenced by the 2-site model previously proposed for binding of bisphosphonates to human bone at pH 7.
42 That system is thought to be comprised of a weak, highly populated site where a phosphonate binds into the bone mineral matrix, and a second higher affinity binding site. Binding at the weaker site results in displacement of one phosphonate group per ligand, with the energy required to release that group contributing to the binding free energy. For the H 5 XT ligand, binding to HAP observed by ITC is complex, but relatively weak overall (apparent K a of 1.9 (AE0.4) Â 10 2 M À1 at pH 5), and therefore more consistent with the characteristics of the weaker site described above. As with weak-binding bisphosphonates, H 5 XT uptake is therefore likely characterized by relatively high rates of desorption. The ITC studies, while further emphasizing the complexity of the systems, do provide an insight into manner in which these two complexes behave in vivo. The data clearly shows that Hdpp has no affinity for HAP and -due to the thermodynamic stability of the tris complex -readily releases the metal ion under physiological conditions. This leads to a plasma clearance and tissue biodistribution akin to what one would expect for La 3+ ions free from a specic chelator. 41 Conversely H 5 XT incorporates functionality which not only gives a more thermodynamically stable metal complex, but possesses its own binding affinity for bone mineral as evidenced by the ITC data. This explains the subtle differences in the in vivo results, in particular the bone biodistribution, and provides a valuable indicator as to the type of design motif that should be targeted in the quest for a new drug.
The uptake of La 3+ by HAP was also investigated in a more traditional batch experiment. The rate of La 3+ depletion in the supernatant was monitored by incubating solutions containing La 3+ and either Hdpp or H 5 XT with a suspension of excess HAP at pH 7.4 and 37 C; the relative distributions of La 3+ in the supernatant were then followed over regular time intervals by ICP-MS (Fig. 7) . In the case of La(dpp) 3 (Fig. 7Ai) , in which distribution of the ligand was also followed by UV-Vis, the data show that, within the error of the experiment, the ligand remains unbound whilst the free metal ion rapidly binds to HAP (greater than 80% in the rst 15 minutes). This supports the ITC data that shows that, in the La(dpp) 3 system, only the metal ion exhibits any affinity for HAP. In the case of La(XT) (Fig. 7Bi) , the ICP-MS data show less than 20% of La 3+ is bound to HAP aer 4 h, and the La 3+ sorption process is characterized by uptake kinetics that are considerably slower than recorded for the corresponding La(dpp) 3 system. Unfortunately the distribution of H 5 XT could not be followed by UV-Vis spectroscopy due to the absence of a chromophore within the ligand. Both ndings are consistent with the much higher stability La(XT) 2À complex (relative to the dominant La(dpp) 2+ complex in the other system) and the relatively weak net exchange of Ca 2+ for La 3+ within HAP when the lanthanum is presented in solution as La(XT) 2À .
In an effort to elucidate rate constants for the binding of La
to HAP in the presence of either ligand system, the experiment was repeated with measurements taken at regular early time points. The data show that, for both Hdpp (Fig. 7Aii ) and H 5 XT (Fig. 7Bii) , there is an initial, rapid association of La 3+ to HAP in the rst 30 seconds, followed by an apparent release of the metal ion, followed by steadier binding consistent with the kinetics of the later time points. This suggests that there are at least two overlapping kinetic processes occurring which are independent of the ligand present. Though this prevents the In contrast to this, H 5 XT is able to bind HAP in the absence of La 3+ and also alters the binding energy and kinetics with La 3+ .
The increase in complexity of the system when La 3+ is introduced in the form of chelate complexes is also evident when the in vivo results are compared with in vitro studies. The presence of either Hdpp or H 5 XT had a notable inuence in vitro and in vivo on the binding of La 3+ to HAP as evident in ITC and in the biodistribution of La 3+ in bone. It is known that, for any La 3+ complex, the route of administration (oral or intravenous), the quantities used and the chemical speciation of the forms that reach the blood will generates complex differences that complicate any comparisons. This makes comparison of the two reported La 3+ complexes with the clinically approved lanthanum carbonate. However it is known that La accumulation is time-dependent and longer term studies are currently underway to assess the effects over a longer period of time. Distribution and uptake of lanthanum within bone cannot be accurately determined from the acute study reported here as the time of the bone remodelling cycle falls outside the studies timeline. Therefore, we are currently undertaking a chronic study to assess the bone uptake, distribution within bone and effect on microarchitecture.
Conclusions
This study examines the lanthanum complexes of two compounds, Hdpp and a phosphinate-EDTA derivative H 5 XT, as potential treatments for bone resorption disorders. We have demonstrated that La 3+ accumulates in the bone following IV dose of either La(dpp) 3 or La(XT) with the latter showing slightly higher uptake. These results provide strong evidence that higher denticity chelators, such as H 5 XT, which lead to complexes with greater inherent thermodynamic stability are needed in order to truly inuence the in vivo behaviour of the lanthanum ions. In addition we have conducted a thorough investigation into the binding kinetics between La 3+ and hydroxyapatite in the presence of either ligand system, using various techniques and under various conditions, shedding some light onto what is both a fascinating and highly complex binding interaction. This study suggests further in vivo experiments are called for to assess their drug candidacies.
Experimental
General High purity water (18.2 MU cm, ELGA Purelab Options and ELGA Purelab Ultra) was used in all experiments. All glassware was soaked overnight in HNO 3 (5%) and thoroughly rinsed with deionized water followed by MQ water to remove any adventitious metal. Lanthanum perchlorate was purchased from Alfa Aesar and used without further purication. Piperazine and hydroxyapatite were purchased from Sigma-Aldrich. The Ca
2+
and PO 4 3À contents (Ca/P molar ratio of 1.65) for the hydroxyapatite used in this study were determined by ICP-OES and further characterized using TGA, BET analysis and powder XRD as reported previously. 31,37 All metal-ion solutions were prepared the day of use. Lanthanum standard (1000 mg mL À1 in 2% HNO 3 ) for ICP-MS was purchased from High Purity Standards.
Synthesis
La(dpp) 3 and La(XT) were prepared according to previously published methods with slight modications. [30] [31] [32] Briey, for La(dpp) 3 : commercially available Hdpp (346 mg, 2.49 mmol) and La(NO 3 ) 3 $6H 2 O (359 mg, 0.83 mmol) were taken up in 3 mL of deionized water and gently heated and stirred until the ligand had completely dissolved. The pH was very slowly raised with 1 M KOH until a basic pH was obtained. Aer 3 hours, a white precipitate had formed which was collected by ltration and washed 3 times with cold methanol and dried on a high vacuum overnight. For La(dpp) 3 For La(XT): iminodiacetic acid (5.4 g, 40.6 mmol) was suspended in 6 M HCl (10 mL) and stirred and heated to reux. Hypophosphorous acid (50% w/w, 2.1 mL, 20.3 mmol) was added, followed by the dropwise addition of formaldehyde (37% w/w, 6.4 mL, 80 mmol). Aer 8 hours, H 5 XT was obtained as the HCl salt as a white precipitate which was collected by ltration and washed with cold methanol followed by cold acetone. H 5 -XT$HCl (91 mg, 0.23 mmol) and La(NO 3 ) 3 $6H 2 O (100 mg, 0.23 mmol) were waken up in 2 mL of deionized water and stirred. Dropwise addition of 1 M KOH initially caused a white precipitate to form, which gradually dissolved as a basic pH range was obtained. The crude reaction mixture was evaporated, and the residual white solid was taken up in the minimum volume of H 2 O, and precipitated with excess of a 1 : 1 mixture of methanol and acetone. The nal product was collected by ltration, washed with acetone, and dried on a high vacuum overnight. 
Acid digestion for ICP-MS analysis
Lanthanide concentration for both in vivo and in vitro studies were determined by ICP-MS analysis by the method reported previously. 30 In brief, samples were dried (vacuum centrifugation) and dissolved in conc. nitric acid (Optima) and slowly heated to 105 C over 1 h and maintained at 105 C for 24 h.
Hydrogen peroxide (approximately 2 mL) was added and samples heated at 140 C for 24 h. Samples were evaporated to dryness at 150 C before redissolving in 3 mL of 10% nitric acid (with 10 ppm Rh) prior to analysis by ICP-MS.
General animal studies
All animal study protocols were approved by The University of British Columbia's Animal Care Committee. Female Sprague Dawley (SD) rats (290-320 g body weight) were purchased from Charles River Laboratories (Wilmington, MA, USA).
Plasma clearance and pharmacokinetics of La(dpp) 3 Solutions of La(dpp) 3 were prepared in 10% DMSO and the stability of the complex over time (7 days) monitored by spectrophotometric methods. The solution of La(dpp) 3 was administered to the animals through cannulae implanted in their jugular veins (n ¼ 6). The animals received a dose of 1 mg kg
À1
at time 0 h and blood samples (0.25 mL were withdrawn at predose, 5, 10, 15, 30 min and 1, 2, 3, 4, 6, 10, 24, 48, 72, 96 and 144 h post-dose). The animals were sacriced following the last time point and the spleen, liver, kidney, lungs, heart and brain were collected. Lanthanide concentrations were determined by ICP-MS analysis following acid digestion of the samples. The calibration curves were linear in the range of 0.1-100 ng mL À1 and 1-50 ng mL À1 in the organs and plasma; respectively. The plasma pharmacokinetic parameters were derived by noncompartmental analysis of plasma concentration-time proles using Phoenix soware (Ver. 1.3).
Solutions of La(dpp) 3 and La(XT) (1 mg mL À1 ) were prepared in 10% DMSO and stored at 4 C. Animals were administered with a dose of 1 mg kg À1 once daily for 5 consecutive days by intravenous injection via jugular vein port. The animals were sacriced on the day of the 5th dose and the spleen liver, kidney lungs, heart, brain and bones were collected. Blood samples (0.5 mL) were withdrawn at pre-dose and post-dose. The blood was centrifuged for 10 min at 50 000 rpm at room temperature to obtain the plasma. For organ homogenization, 1 g organ was added to 2 mL normal saline. Bones were cleaned manually of all so esh and sectioned into knee, middle, and hip parts using a ceramic blade, and lyophilized prior to normal acid digestion.
Isothermal titration calorimetry
ITC experiments in the presence of ligand (Hdpp or XT) were carried out in either piperazine (100 mM) pH 5 or HEPES (100 mM) pH 7.4. Titrations were performed by injecting consecutive 10 mL aliquots of ligand (2.5-80 mM) or metal ion/ligand solution (2.5/10 mM for Hdpp and 81/90 mM for XT) into the ITC cell (volume ¼ 1.4 mL) containing hydroxyapatite (0.1-1.5 mM) suspension. Hydroxylapatite suspensions were prepared by adding the required amount of hydroxyapatite to the appropriately buffered solution followed by sonication for 5 minutes. The ITC cell was stirred continuously during the titration. Control experiments (heats of dilution) were performed by titration of ligand or metal ion/ligand solution into buffer containing no hydroxyapatite. Each ITC experiment was performed in triplicate (at least). The error associated with diffusion from the syringe during baseline equilibration, the rst injection was only 5 mL, and the associated small heat was not included in the data analysis.
Hydroxyapatite binding studies
All time points were run in triplicate. Samples containing 10 mg of hydroxyapatite (Sigma-Aldrich) were initially incubated and agitated (37 C, 220 rpm) with 0.9 mL HEPES buffer (100 mM, pH 7.4) in 1.5 mL Eppendorfs for 24 hours. Stock solutions (1.0 mM) of La(dpp) 3 and La(XT) were prepared from the premade complexes dissolved in HEPES buffer. At the outset of the experiment, 100 mL of either stock solution was added to a sample and incubated and agitated for a set time. When the time point was reached, the supernatant was carefully removed, taking care not to disturb the residual HAP, and ltered through a 22 micron frit. An accurately weighed aliquot (100 mg) of the supernatant was prepared for ICP-MS analysis using the digestion and evaporation protocol as described for in vivo studies. Samples containing La(dpp) 3 were also analysed by UV-Vis spectroscopy to determine Hdpp concentration. Zero time points were simulated by preparing samples containing no HAP. Background La 3+ levels were corrected for against samples containing no complex. 
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